Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions... Show more
Axon Enterprise has evolved from a TASER hardware maker into an integrated public-safety technology platform spanning body cameras, cloud software, drones, robotics, and AI-driven analytics. This ecosystem approach — where hardware acts as a sensor feeding into cloud software — creates a structural advantage over single-product competitors, because each added capability makes the broader system more valuable and harder to displace.
Management estimates the company is only about 15% penetrated within its U.S. state and local market, with a total addressable market (TAM) of roughly $159 billion to $160 billion. That leaves substantial room for cross-selling and upselling. Software and services have become the higher-margin, faster-growing layer, with ARR climbing about 39% year over year and software increasingly outpacing hardware growth. Axon's long-term targets of $6 billion in annual revenue and a 28% adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin by 2028 frame an ambition to scale profitably while reinvesting in innovation.
Several developments could shape the stock's trajectory over the coming quarters. First, quarterly earnings remain a focal point, as management raised its full-year 2026 revenue growth outlook to 32%–34%, driven by broad demand across public safety, international, federal, and enterprise markets. Continued execution against that guidance will be closely watched.
Second, the AI product pipeline — including Draft One (automated report writing), Axon Assistant, Axon Vision, and the Axon Gravity data initiative — represents a potentially transformative catalyst as agencies move from trials to broader deployment. Third, the counter-drone franchise, bolstered by the Safer Skies Act's $250 million in federal grants, offers a policy-driven tailwind. Finally, analyst activity remains active: firms such as RBC Capital (Outperform, $860), Piper Sandler (Overweight, $893), and Morgan Stanley (Overweight) have been constructive, while UBS has been more cautious (Neutral, $610), underscoring a mixed but broadly positive consensus stance with average price targets near the low-to-mid $800s.
Axon's trajectory is tied to several macro and policy factors. Public-safety budgets are relatively resilient, but municipal spending can be sensitive to local tax revenues and interest rates. Higher rates can raise financing costs for government procurement, while easing inflation could relieve pressure on component costs, such as memory, that currently weigh on margins.
Geopolitical and security concerns have amplified demand for counter-drone and surveillance technology, particularly around major events like the World Cup and the Olympics. At the same time, technology-adoption trends — especially AI and automation to address chronic law-enforcement staffing shortages — align directly with Axon's product strategy. The regulatory climate remains a watch item, as privacy, data-security, and AI-ethics scrutiny could influence deployment speed and shape the pace of AI adoption.
The Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, exchange-traded fund (ETF), or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support more informed decision-making. Traders looking to complement fundamental research with AI-driven signals may find the Trend Prediction Engine a useful addition to their analytical toolkit.
Looking toward 2026 and beyond, several structural themes could define Axon's future outlook. Market expansion remains the largest opportunity, with international, federal, and enterprise customers offering significant runway beyond the mature U.S. public-safety base. Cost-structure evolution will matter as management balances rapid growth with margin sustainability, targeting meaningful EBITDA margin expansion by 2028.
Technology transitions — particularly the shift toward AI-enabled software and the integration of drones as first responders (DFR) — should continue reshaping the company's revenue mix toward higher-margin, recurring streams. Competitive threats persist from established players such as Motorola Solutions, while regulatory developments around AI and data governance could influence adoption timelines. Capital allocation priorities, including strategic acquisitions like Fusus and Dedrone, suggest management will keep investing ahead of growth. Consensus analyst expectations, with a generally positive rating profile and average price targets near the low-to-mid $800s, reflect optimism about these long-term drivers, though near-term execution and valuation remain key variables to monitor.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | +2.71% | ||
| TECH - AXON | 61% Loosely correlated | +0.05% | ||
| VCYT - AXON | 58% Loosely correlated | -1.22% | ||
| BEAM - AXON | 57% Loosely correlated | -4.99% | ||
| SEER - AXON | 56% Loosely correlated | -1.26% | ||
| ADPT - AXON | 56% Loosely correlated | -1.49% | ||
More | ||||
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 115 similar instances where the Aroon Indicator formed such a pattern. In 95 of the 115 cases the stock moved lower. This puts the odds of a downward move at 83%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 49 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 27 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).